Shared tumor-associated antigen peptide–MHC complex (TAA-pMHC)

Shared tumor-associated antigen (TAA) peptide–MHC complexes are molecular targets for T-cell-based immunotherapies, consisting of a specific peptide fragment derived from a TAA bound to a Major Histocompatibility Complex (MHC) molecule on the cell surface (Nature Reviews Drug Discovery, 2021). Unlike neoantigens, which are unique to tumors, TAAs are self-antigens that are overexpressed in malignant cells but also expressed at varying levels in healthy tissues (NCI Dictionary). This shared expression pattern makes them attractive for broad clinical application across patient populations but poses a significant risk of "on-target, off-tumor" toxicity, where the immune system attacks normal cells presenting the same pMHC complex (Blood, 2013). Therapeutic strategies targeting these complexes include T-cell receptor (TCR) engineered T-cells and bispecific TCR-mimetic antibodies like Tebentafusp (FDA, 2022). Successful targeting requires careful selection of antigens with a high tumor-to-normal tissue expression ratio to minimize adverse effects. These complexes are central to the development of "off-the-shelf" immunotherapies that do not require patient-specific sequencing (Frontiers in Immunology, 2020). The presentation of these peptides is restricted by the patient's HLA type, necessitating HLA-matching for treatment eligibility (Journal of Hematology & Oncology, 2019). Clinical trials have demonstrated both the high potency of targeting these complexes and the potential for severe toxicity if the target peptide is present in vital organs (Journal of Clinical Oncology, 2015). Monitoring for antigen loss or HLA downregulation is crucial, as these are common mechanisms of resistance to pMHC-targeted therapies (Cancer Discovery, 2021). Overall, TAA-pMHC complexes represent a major class of targets in the evolving landscape of precision oncology.

Other names

Tumor-associated antigen-MHC complexTAA-HLA complexShared antigen-HLA complexCancer-testis antigen pMHC

T-cell receptor (TCR) mediated recognition of peptide-HLA complexes leading to T-cell activation and tumor cell lysis.